Is There a Future for Viking Therapeutics?

Viking Therapeutics (VKTX) has seen its stock recover following initial investor concern over a 20% discontinuation rate in the phase 2 trial of its oral weight-loss drug, VK2735. The rebound is justified by a closer examination of the trial data, which revealed an unusually high placebo group discontinuation rate, and the company's strategic pivot to explore oral VK2735 as a maintenance dose in combination with its promising subcutaneous formulation. This new path, with results for the maintenance strategy expected in 2026 and subcutaneous phase 3 results in 2027, provides a clearer commercialization trajectory for the oral drug and strengthens VKTX's competitive position against rivals like Novo Nordisk and Eli Lilly.

Analysis

Viking Therapeutics (VKTX) experienced a stock sell-off following a 20% discontinuation rate in its oral VK2735 Phase 2 trial, despite demonstrated efficacy. However, the subsequent recovery in the stock price is justified by a deeper analysis of the trial data. The placebo group in the Phase 2 trial exhibited an unusually high 13% discontinuation rate, exceeding rates seen in competitor Phase 3 trials, suggesting a potentially difficult participant cohort rather than inherent drug issues.

Management has strategically initiated a new Phase 1 trial for oral VK2735, exploring its use as a maintenance dose in combination with the subcutaneous formulation. This pivot aims to provide a clear commercialization pathway for the oral drug, with results anticipated in 2026. Meanwhile, the subcutaneous VK2735 formulation, which showed excellent Phase 2 results, is currently in Phase 3 trials with data expected in 2027.

This dual-formulation strategy positions Viking Therapeutics as a viable alternative to established GLP-1/GIP agonist market leaders like Novo Nordisk and Eli Lilly. The overall sentiment towards VKTX is strongly positive (0.8 per-ticker sentiment), reflecting optimism surrounding its pipeline and strategic adjustments.

Key Decisions for Investors

• Investors should closely monitor the upcoming 2026 results for the oral VK2735 maintenance dose trial and the 2027 Phase 3 results for the subcutaneous formulation, as these represent significant catalysts.
• Evaluate Viking Therapeutics' evolving competitive positioning against established players like Novo Nordisk and Eli Lilly, particularly as its dual-formulation strategy progresses.
• Consider the long-term commercial potential of VKTX, given the strategic pivot for its oral drug and the promising data from its subcutaneous formulation, which could warrant a re-evaluation of its growth trajectory.